128 128
Age-related clonal hematopoiesis associated with adverse outcomes. N. Engl.
J. Med.
371
, 2488–2498.
Jan, M., Snyder, T.M., Corces-Zimmerman, M.R., Vyas, P., Weissman, I.L.,
Quake, S.R., and Majeti, R. (2012). Clonal evolution of preleukemic hematopoi-
etic stem cells precedes human acute myeloid leukemia. Sci. Transl. Med.
4
,
149ra118.
Kerbauy, D.B., and Deeg, H.J. (2007). Apoptosis and antiapoptotic mecha-
nisms in the progression of myelodysplastic syndrome. Exp. Hematol.
35
,
1739–1746.
Kim, J., and Zaret, K.S. (2015). Reprogramming of human cancer cells to plu-
ripotency for models of cancer progression. EMBO J.
34
, 739–747.
Kim, J., Hoffman, J.P., Alpaugh, R.K., Rhim, A.D., Reichert, M., Stanger, B.Z.,
Furth, E.E., Sepulveda, A.R., Yuan, C.X., Won, K.J., et al. (2013). An iPSC line
from human pancreatic ductal adenocarcinoma undergoes early to invasive
stages of pancreatic cancer progression. Cell Rep.
3
, 2088–2099.
Kotini, A.G., Chang, C.J., Boussaad, I., Delrow, J.J., Dolezal, E.K.,
Nagulapally, A.B., Perna, F., Fishbein, G.A., Klimek, V.M., Hawkins, R.D.,
et al. (2015). Functional analysis of a chromosomal deletion associated with
myelodysplastic syndromes using isogenic human induced pluripotent stem
cells. Nat. Biotechnol.
33
, 646–655.
Link, D.C., and Walter, M.J. (2016). ’CHIP’ping away at clonal hematopoiesis.
Leukemia
30
, 1633–1635.
Martincorena, I., and Campbell, P.J. (2015). Somatic mutation in cancer and
normal cells. Science
349
, 1483–1489.
Ng, E.S., Davis, R., Stanley, E.G., and Elefanty, A.G. (2008). A protocol
describing the use of a recombinant protein-based, animal product-free me-
dium (APEL) for human embryonic stem cell differentiation as spin embryoid
bodies. Nat. Protoc.
3
, 768–776.
Notta, F., Zandi, S., Takayama, N., Dobson, S., Gan, O.I., Wilson, G.,
Kaufmann, K.B., McLeod, J., Laurenti, E., Dunant, C.F., et al. (2016). Distinct
routes of lineage development reshape the human blood hierarchy across
ontogeny. Science
351
, aab2116.
Pandolfi, A., Barreyro, L., and Steidl, U. (2013). Concise review: preleukemic
stem cells: molecular biology and clinical implications of the precursors to
leukemia stem cells. Stem Cells Transl. Med.
2
, 143–150.
Papaemmanuil, E., Gerstung, M., Malcovati, L., Tauro, S., Gundem, G., Van
Loo, P., Yoon, C.J., Ellis, P., Wedge, D.C., Pellagatti, A., et al.; Chronic
Myeloid Disorders Working Group of the International Cancer Genome
Consortium (2013). Clinical and biological implications of driver mutations in
myelodysplastic syndromes. Blood
122
, 3616–3627, quiz 3699.
Papaemmanuil, E., Gerstung, M., Bullinger, L., Gaidzik, V.I., Paschka, P.,
Roberts, N.D., Potter, N.E., Heuser, M., Thol, F., Bolli, N., et al. (2016).
Genomic classification and prognosis in acute myeloid leukemia. N. Engl. J.
Med.
374
, 2209–2221.
Papapetrou, E.P. (2016). Patient-derived induced pluripotent stem cells in
cancer research and precision oncology. Nat. Med.
22
, 1392–1401.
Papapetrou, E.P., and Sadelain, M. (2011). Generation of transgene-free
human induced pluripotent stem cells with an excisable single polycistronic
vector. Nat. Protoc.
6
, 1251–1273.
Papapetrou, E.P., Tomishima, M.J., Chambers, S.M., Mica, Y., Reed, E.,
Menon, J., Tabar, V., Mo, Q., Studer, L., and Sadelain, M. (2009).
Stoichiometric and temporal requirements of Oct4, Sox2, Klf4, and c-Myc
expression for efficient human iPSC induction and differentiation. Proc. Natl.
Acad. Sci. USA
106
, 12759–12764.
Papapetrou, E.P., Lee, G., Malani, N., Setty, M., Riviere, I., Tirunagari, L.M.,
Kadota, K., Roth, S.L., Giardina, P., Viale, A., et al. (2011). Genomic safe
harbors permit high
b
-globin transgene expression in thalassemia induced
pluripotent stem cells. Nat. Biotechnol.
29
, 73–78.
Pellagatti, A., Cazzola, M., Giagounidis, A., Perry, J., Malcovati, L., Della Porta,
M.G., J
€
adersten, M., Killick, S., Verma, A., Norbury, C.J., et al. (2010).
Deregulated gene expression pathways in myelodysplastic syndrome
hematopoietic stem cells. Leukemia
24
, 756–764.
Sanjuan-Pla, A., Macaulay, I.C., Jensen, C.T., Woll, P.S., Luis, T.C., Mead, A.,
Moore, S., Carella, C., Matsuoka, S., Bouriez Jones, T., et al. (2013). Platelet-
biased stem cells reside at the apex of the haematopoietic stem-cell hierarchy.
Nature
502
, 232–236.
Sato, T., Kim, S., Selleri, C., Young, N.S., and Maciejewski, J.P. (1998).
Measurement of secondary colony formation after 5 weeks in long-term cul-
tures in patients with myelodysplastic syndrome. Leukemia
12
, 1187–1194.
Shlush, L.I., Zandi, S., Mitchell, A., Chen, W.C., Brandwein, J.M., Gupta, V.,
Kennedy, J.A., Schimmer, A.D., Schuh, A.C., Yee, K.W., et al.; HALT Pan-
Leukemia Gene Panel Consortium (2014). Identification of pre-leukaemic hae-
matopoietic stem cells in acute leukaemia. Nature
506
, 328–333.
Sperling, A.S., Gibson, C.J., and Ebert, B.L. (2017). The genetics of myelodys-
plastic syndrome: from clonal haematopoiesis to secondary leukaemia. Nat.
Rev. Cancer
17
, 5–19.
Steensma, D.P., Bejar, R., Jaiswal, S., Lindsley, R.C., Sekeres, M.A.,
Hasserjian, R.P., and Ebert, B.L. (2015). Clonal hematopoiesis of indetermi-
nate potential and its distinction from myelodysplastic syndromes. Blood
126
, 9–16.
Subramanian, A., Tamayo, P., Mootha, V.K., Mukherjee, S., Ebert, B.L.,
Gillette, M.A., Paulovich, A., Pomeroy, S.L., Golub, T.R., Lander, E.S., and
Mesirov, J.P. (2005). Gene set enrichment analysis: a knowledge-based
approach for interpreting genome-wide expression profiles. Proc. Natl.
Acad. Sci. USA
102
, 15545–15550.
Themeli, M., Kloss, C.C., Ciriello, G., Fedorov, V.D., Perna, F., Gonen, M., and
Sadelain, M. (2013). Generation of tumor-targeted human T lymphocytes
from induced pluripotent stem cells for cancer therapy. Nat. Biotechnol.
31
,
928–933.
Valk, P.J., Verhaak, R.G., Beijen, M.A., Erpelinck, C.A., Barjesteh van Waalwijk
van Doorn-Khosrovani, S., Boer, J.M., Beverloo, H.B., Moorhouse, M.J., van
der Spek, P.J., Lo¨ wenberg, B., and Delwel, R. (2004). Prognostically useful
gene-expression profiles in acute myeloid leukemia. N. Engl. J. Med.
350
,
1617–1628.
Vo, L.T., and Daley, G.Q. (2015). De novo generation of HSCs from somatic
and pluripotent stem cell sources. Blood
125
, 2641–2648.
Walter, M.J., Shen, D., Ding, L., Shao, J., Koboldt, D.C., Chen, K., Larson, D.E.,
McLellan, M.D., Dooling, D., Abbott, R., et al. (2012). Clonal architecture of
secondary acute myeloid leukemia. N. Engl. J. Med.
366
, 1090–1098.
Walter, M.J., Shen, D., Shao, J., Ding, L., White, B.S., Kandoth, C., Miller, C.A.,
Niu, B., McLellan, M.D., Dees, N.D., et al. (2013). Clonal diversity of recurrently
mutated genes in myelodysplastic syndromes. Leukemia
27
, 1275–1282.
Will, B., Zhou, L., Vogler, T.O., Ben-Neriah, S., Schinke, C., Tamari, R., Yu, Y.,
Bhagat, T.D., Bhattacharyya, S., Barreyro, L., et al. (2012). Stem and progen-
itor cells in myelodysplastic syndromes show aberrant stage-specific expan-
sion and harbor genetic and epigenetic alterations. Blood
120
, 2076–2086.
Wlodarski, M.W., Hirabayashi, S., Pastor, V., Stary´, J., Hasle, H., Masetti, R.,
Dworzak, M., Schmugge, M., van den Heuvel-Eibrink, M., Ussowicz, M.,
et al.; EWOG-MDS (2016). Prevalence, clinical characteristics, and prognosis
of GATA2-related myelodysplastic syndromes in children and adolescents.
Blood
127
, 1387–1397, quiz 1518.
Woll, P.S., Kj
€
allquist, U., Chowdhury, O., Doolittle, H., Wedge, D.C.,
Thongjuea, S., Erlandsson, R., Ngara, M., Anderson, K., Deng, Q., et al.
(2014). Myelodysplastic syndromes are propagated by rare and distinct hu-
man cancer stem cells in vivo. Cancer Cell
25
, 794–808.
Woolthuis, C.M., and Park, C.Y. (2016). Hematopoietic stem/progenitor cell
commitment to the megakaryocyte lineage. Blood
127
, 1242–1248.
Xie, M., Lu, C., Wang, J., McLellan, M.D., Johnson, K.J., Wendl, M.C.,
McMichael, J.F., Schmidt, H.K., Yellapantula, V., Miller, C.A., et al. (2014).
Age-related mutations associated with clonal hematopoietic expansion and
malignancies. Nat. Med.
20
, 1472–1478.
328
Cell Stem Cell
20
, 315–328, March 2, 2017